Indefinite Delivery Contract HHSN261201200020I
Award Date 9/20/12
Last Date to Order 9/19/14
Federal Agency
Awardee
Ultimate Awardee
NAICS Category
Federal Contract Vehicle
Pricing Type
Order Dependent (IDV only)
Legislative Mandate
Not listed National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed Similar IDVs
- This is a multiple award Indefinite Delivery Contract (IDC) issued by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services. The contract has a ceiling value of $9,950,000 and was awarded to the University of Oklahoma (OU) to provide preclinical research and development services related to cancer prevention and treatment. The task orders issued under this IDC cover a range of preclinical oncology research activities, including the evaluation of...
- This indefinite delivery contract was awarded by the National Cancer Institute (NCI), a civilian agency under the Department of Health and Human Services, to the University of Oklahoma (OU) to support the PREVENT Cancer Preclinical Drug Development Program. The $149,995,000 IDIQ contract covers the continued evaluation of the efficacy and pharmacodynamic/efficacy biomarkers of potential cancer preventive agents, as well as preclinical product development, manufacturing, and...
- The University of Oklahoma Health Sciences Center (OUHSC) was awarded a Basic Ordering Agreement (BOA) contract by the Bureau of Medicine and Surgery, a Defense agency, with a ceiling value of $0.00. This single-award IDV contract has an ultimate completion date of April 30, 2035. Under this BOA, OUHSC provides a wide range of biomedical research, healthcare, scientific services, and educational programs to multiple federal agencies, including the Department of Veterans Affairs, U.S....
- The federal contract IDV award was issued by the National Cancer Institute (NCI) for "Preclinical In Vitro and In Vivo Agent Development Assays" with a ceiling value of $0. The multiple-award IDC has a parent master IDIQ contract titled "Preclinical Agent Development Assays 2012-2016" and was awarded to the University of Alabama at Birmingham (UAB) on September 20, 2012, with an ultimate completion date of September 19, 2014. Under this IDC, UAB has been issued several...
- The contract IDV award is for the PREVENT Cancer Preclinical Drug Development Program, a multiple-award IDIQ contract administered by the National Cancer Institute (NCI). The program encompasses three main technical areas: (1) evaluation of the efficacy and pharmacodynamic/efficacy biomarkers for potential cancer preventive agents, (2) preclinical product development, analytical testing, process development, and cGMP manufacturing support for cancer preventive vaccines, and (3) pharmacological...
- The federal contract IDV is an Indefinite Delivery Contract (IDC) awarded by the National Cancer Institute (NCI), which is part of the Department of Health and Human Services (HHS) and the National Institutes of Health (NIH). The prime contractor is the Public Health Institute (PHI), a non-profit organization. The IDC, valued at $275,000,000, is for the Surveillance, Epidemiology, and End Results (SEER) program, which conducts cancer epidemiology research and surveillance. Under this IDC, PHI...
- This indefinite delivery contract was awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to the University of Alabama at Birmingham (UAB) to support the agency's Preclinical Prevent Cancer Program. The program focuses on evaluating the preclinical efficacy and identifying intermediate biomarkers for potential cancer prevention agents prior to clinical trials. Under this $29.8 million multiple-award IDC, UAB has been issued multiple...
- The Indefinite Delivery Contract (IDC) with ID 75N91024D00006 was awarded by the National Cancer Institute (NCI), a civilian agency, to the Weill Medical College of Cornell University. This multiple-award IDC, with a ceiling value of $149,995,000, supports the PREVENT Cancer Preclinical Drug Development Program through the provision of preclinical research services. The IDC's scope includes evaluating the efficacy of potential cancer preventive agents, identifying relevant biomarkers, developing...
- This federal contract IDV award by the National Cancer Institute (NCI), a civilian agency, provides for research and development services to support preclinical pharmacokinetic and pharmacology evaluations of agents being developed for cancer patients. The prime contractor is the University of Pittsburgh - Of The Commonwealth System of Higher Education, a major public research university with extensive experience conducting federal research contracts and grants across biomedical sciences. The...
- This indefinite delivery contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health within the Department of Health and Human Services, to IIT Research Institute (IITRI), a non-profit contract research organization. The $74,995,000 multiple-award contract, titled the "PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarkers," supports preclinical efficacy and biomarker evaluation, manufacturing, and...
Name | Description | Awardee | Potential Value | AwardDate | CompletionDate | Updated At |
|---|---|---|---|---|---|---|
Delivery Order HHSN261201200020I-HHSN26100007 | University Of Oklahoma | $607.1k | 9/12/14 | 9/11/17 | 8/21/18 | |
Delivery Order HHSN261201200020I-HHSN26100002 | University Of Oklahoma | $770.8k | 9/20/12 | 9/19/15 | 9/11/14 | |
Delivery Order HHSN261201200020I-HHSN26100001 | University Of Oklahoma | $1.9k | 9/20/12 | 9/19/14 | 3/2/16 | |
Delivery Order HHSN261201200020I-HHSN26100006 | University Of Oklahoma | $474.2k | 8/26/14 | 8/25/17 | 5/21/18 | |
Delivery Order HHSN261201200020I-HHSN26100005 | University Of Oklahoma | $633.9k | 9/18/13 | 9/17/16 | 5/15/18 |